Evidence map›Paper›PMID 34815467›Full record

ArticleScientific reports2021

A comprehensive breath test that confirms recent use of inhaled cannabis within the impairment window.

Michael W DeGregorio, Gregory T Wurz, Edward Montoya, Chiao-Jung Kao

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Michael W DeGregorioRCU Labs, Inc., 408 Sunrise Avenue, Roseville, CA, 95661-4123, USA. mdegregorio@rculabs.com.
Gregory T WurzRCU Labs, Inc., 408 Sunrise Avenue, Roseville, CA, 95661-4123, USA.
Edward MontoyaRCU Labs, Inc., 408 Sunrise Avenue, Roseville, CA, 95661-4123, USA.
Chiao-Jung KaoRCU Labs, Inc., 408 Sunrise Avenue, Roseville, CA, 95661-4123, USA.
Parker Institute for Cancer Immunotherapy · US

Funding

RCU Labs, Inc. Institutional funds
6 · The paper itself

Abstract

Legalization of cannabis for medicinal and/or recreational use is expanding globally. Although cannabis is being regulated country by country, an accurate recent use test with indisputable results correlated with impairment has yet to be discovered. In the present study, a new approach for determining recent cannabis use within the impairment window after smoking was developed by studying 74 subjects with a mean age of 25 years and average use history of 9 years. Horizontal gaze nystagmus was evaluated along with subject self-assessments of impairment, and blood and breath samples were collected before and after smoking cannabis. Breath and blood pharmacokinetic parameters and cannabinoid profiles determined recent use within the impairment window. No subjects were positive for recent use pre-smoking, although all subjects had detectable cannabinoids in breath samples. We describe an inhaled cannabis recent use test that correlates with impairment and helps protect against wrongful prosecution and workplace discrimination.

Indexed as

Administration, InhalationAdultBreath TestsCannabinoidsCannabisFemaleHumansMaleMiddle AgedSubstance Abuse DetectionYoung AdultCannabinoids

Identifiers

PMID34815467
PMCPMC8611040
OpenAlexW3200434223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.